This ticker has not been starred yet KROS Keros Therapeutics, Inc.
Pharmaceutical Preparations
Book value per $ invested $ 0.75
Leverage 10.32%
Market Cap $ 405.5m
PE 4.66
Dividend Yield 0.00%
Profit $ 87.0m
Margin 35.84%

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.

Subscribe Now For Access - Only $1.99 Per Month